上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Alrizomadlin (Synonyms: APG-115; AA-115) 纯度: 98.05%
Alrizomadlin (APG-115) 是一种口服活性小分子 MDM2 蛋白抑制剂, 可与 MDM2 蛋白结合,IC50 值和 Ki 值分别为3.8 nM 和 1 nM。Alrizomadlin 可阻断 MDM2 与 p53 的相互作用并且以 p53 依赖性方式诱导细胞周期停滞和凋亡 (apoptosis)。
Alrizomadlin Chemical Structure
CAS No. : 1818393-16-6
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
1 mg | ¥3800 | In-stock | |
5 mg | ¥8500 | In-stock | |
10 mg | ¥14000 | In-stock | |
50 mg | 询价 | ||
100 mg | 询价 |
* Please select Quantity before adding items.
Alrizomadlin 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- Clinical Compound Library Plus
- Bioactive Compound Library Plus
生物活性 |
Alrizomadlin (APG-115) is an orally active MDM2 protein inhibitor binding to MDM2 protein with IC50 and Ki values of 3.8 nM and 1 nM, respectively[1]. Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and apoptosis in a p53-dependent manner[2][3]. |
IC50 & Target |
IC50: 3.8 nm (APG-115)[1] |
||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
Alrizomadlin (0.001-100 μM; 72 hours) inhibits cell proliferation in concentration-dependent manner, with IC50s of 18.9 ± 15.6 nM and 103.5 ± 18.3 nM respectively in AGS and MKN45 cells[3]. Alrizomadlin (0.02 μM, 0.2 μM; 48 hours) enhances the anti-proliferative effect of radiotherapy at different radiation dose[3]. Alrizomadlin (0.02 μM, 0.2 μM; 48 hours) affects progression by inducing cells arrested at G0/G1 phase in AGS and MKN45 cell with wild p53[3]. Alrizomadlin (0.02 μM, 0.2 μM; 24 hours) activates p53 to enhance radiosensitivity in AGS and MKN45 cells; stable knockout of p53 abrogates expression of MDM2, p53, p21, PUMA, BAX, Cleaved-caspase3, γH2AX[3]. Alrizomadlin (0.3 μM, 1 μM, 3 μM, 10 μM; 24 hours) leads to a concentration-dependent cell cycle arrest in G2/M phases and a decreasing in S-phase in p53 wide-type cell lines (TPC-1, KTC-1)[4]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay[3]
RT-PCR[3]
Cell Cycle Analysis[3]
Apoptosis Analysis[4]
Western Blot Analysis[3]
|
||||||||||||||||||||||||||||||||||||||||
体内研究 (In Vivo) |
Alrizomadlin (Delivered orally; 100 mg/kg; once daily; 10 days) enhances radiation antitumor effect in gastric adenocarcinoma in vivo[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||||||||||||||||||||||||||
Clinical Trial |
|
||||||||||||||||||||||||||||||||||||||||
分子量 |
642.59 |
||||||||||||||||||||||||||||||||||||||||
Formula |
C34H38Cl2FN3O4 |
||||||||||||||||||||||||||||||||||||||||
CAS 号 |
1818393-16-6 |
||||||||||||||||||||||||||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||||||||||||||||||||||
储存方式 |
|
||||||||||||||||||||||||||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (155.62 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||||||||||||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务